Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | The impact of emicizumab prophylaxis on caregivers’ burden for patients with hemophilia A

Eman Hassan • 3 Apr 2022
BSH 2022
Hemophilia Antibodies Emicizumab

Eman Hassan, MD, Birmingham Children’s Hospital, Birmingham, UK, gives an overview of some results from a study which assessed the impact of emicizumab prophylaxis on caregivers’ burden for pediatric patients with hemophilia A. Dr Hassan first explains the convenient route of administration of emicizumab, as well as its high efficacy and safety profile, which all provide numerous benefits. Following this, Dr Hassan discusses the main aims of this study, and some interesting results, which demonstrate that caregivers’ burden is reduced in all domains when emicizumab is administered. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Eman Hassan

The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
2:40
The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
Eman Hassan • 28 Apr 2024
Unmet need in hemophilia A: breakthrough bleeds
0:51
Unmet need in hemophilia A: breakthrough bleeds
Eman Hassan • 3 Apr 2022
The present and future of hemophilia A treatment
1:23
The present and future of hemophilia A treatment
Eman Hassan • 3 Apr 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals